
Recombinetics Inc Profile last edited on: 1/9/2019
CAGE: 5ECE0
UEI: L99NWZNZ7K57
Business Identifier: Using gene editing tools to breed livestock for biomedical and agricultural applications Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1246 University Avenue West Suite 301
Saint Paul, MN 55104
Saint Paul, MN 55104
(612) 727-2000 |
stephanie@recombinetics.com |
www.recombinetics.com |
Location: Single
Congr. District: 04
County: Ramsey
Congr. District: 04
County: Ramsey
Public Profile
Recombinetics, Inc. is engaged in development of proprietary gene repair and gene-editing technology. The company uses its technologies in the agricultural arena to accelerate the breeding of natural characteristics into pigs and other livestock to enhance their health and welfare, and advance worldwide food production and safety. In the biomedical arena, Recombinetics also applies its genome-editing solutions and TALEN technologies to create viable large animal models for human disease research as part of the development of therapeutic compounds, medical devices, and protocols. With some key in the firm's gene editing technology, Recombinetics is moving on to the commercialization phase with hopes of making big dents in three markets: livestock health, human medical research and regenerative medicine.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NIH | $342,154 | |
Project Title: An Inducible Swine Hepatocellular Carcinoma Platform for Enhanced Therapeutic Development | ||||
2019 | 1 | NIH | $224,773 | |
Project Title: Development and Characterization of a Preclinical Swine Model of Osteogenesis Imperfecta | ||||
2019 | 1 | NIH | $299,188 | |
Project Title: A Swine Model of Glioblastoma | ||||
2019 | 1 | NIH | $300,000 | |
Project Title: Swine Model of Monogenic Diabetes with Potential Implications for T1D, T2D, and Double Diabetes | ||||
2019 | 1 | NIH | $398,952 | |
Project Title: Development and Evaluation of a Thrombospondin 2 Deficient Pig as an Improved Source of Biomaterial |
Key People / Management
Scott C Fahrenkrug -- Founder, President, Chief Executive Officer and Chairman
Jarryd Matthew Campbell
Daniel Fred Carlson
Perry Hackett -- Founder
Derek Matthew Korpela
Tamene Melkamu
Mark Walton -- Chief Marketing Officer
Adrienne Leigh Watson
Justin Zenanko -- CFO
Jarryd Matthew Campbell
Daniel Fred Carlson
Perry Hackett -- Founder
Derek Matthew Korpela
Tamene Melkamu
Mark Walton -- Chief Marketing Officer
Adrienne Leigh Watson
Justin Zenanko -- CFO